LEADER 03540nam  22005055  450 
001 9910300184503321
005 20200630222053.0
010   $a3-642-55086-X
024 7 $a10.1007/978-3-642-55086-7
035   $a(CKB)3710000000277592
035   $a(EBL)1965566
035   $a(SSID)ssj0001386354
035   $a(PQKBManifestationID)11817447
035   $a(PQKBTitleCode)TC0001386354
035   $a(PQKBWorkID)11374687
035   $a(PQKB)10488384
035   $a(DE-He213)978-3-642-55086-7
035   $a(MiAaPQ)EBC1965566
035   $a(PPN)183086414
035   $a(EXLCZ)993710000000277592
100   $a20141106d2015      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aAutoimmune Pancreatitis /$fedited by Terumi Kamisawa, Jae Bock Chung
205   $a1st ed. 2015.
210  1$aBerlin, Heidelberg :$cSpringer Berlin Heidelberg :$cImprint: Springer,$d2015.
215   $a1 online resource (202 p.)
300   $aDescription based upon print version of record.
311   $a3-642-55085-1 
327   $aPreface -- Part 1. Overview of type 1 and type 2 -- Part 2. Epidemiology -- Part 3. Pathophysiology -- Part 4. Pathology -- Part 5. Clinical features -- Part 6. Pancreatic endocrine and exocrine functions -- Part 7. Serology -- Part 8. Diagnostic criteria -- Part 9. Imaging -- Abdominal ultrasonography -- CT and MRI with MRCP -- Endoscopy; ERCP and EUS -- PET-CTNobumasa Mizuno -- Part 10. Tissue acquisition for histologic diagnosis -- Part 11. Other organ involvements -- Sclerosing cholangitis -- Sialadenitis and dacryoadenitis -- Retroperitoneal fibrosis -- Renal lesions -- Pulmonary lesions -- Lymphadenopathy -- GI tract -- Part 12. Treatment -- Steroids -- Immunomodulatory drugs and rituximab -- Relapse -- Part 13. Prognosis -- Development to chronic pancreatitis -- Occurrence of malignant neoplasms -- Part 14. Type 2 AIP -- Part 15. International survey -- Part 16. AIP in the USA -- Part 17. AIP in Europe -- Part 18. Future perspective.
330   $aThis book provides up-to-date information on all aspects of autoimmune pancreatitis, a unique form of pancreatitis characterized clinically by frequent presentation with obstructive jaundice and dramatic response to steroids, histologically by a lymphoplasmacytic infiltrate with fibrosis, and radiologically by pancreatic enlargement. Current concepts regarding the disease and its classification into subtypes 1 and 2 are explained, and clinical, serological, and histopathological findings are carefully described. Imaging features on all the relevant modalities are illustrated, covering both the pancreas and other involved organs. Current and emerging therapeutic strategies, including steroids, immunomodulatory drugs, and rituximab, are then discussed. The reader will find the book to be an excellent aid to the diagnosis of autoimmune pancreatitis and its differentiation from pancreatobiliary malignancies, as well as a clear guide to treatment.
606   $aInternal medicine
606   $aInternal Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H33002
615  0$aInternal medicine.
615 14$aInternal Medicine.
676   $a616.37
702   $aKamisawa$b Terumi$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aChung$b Jae Bock$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910300184503321
996   $aAutoimmune Pancreatitis$91759953
997   $aUNINA